WO2013156977A1 - Solid phase peptide synthesis of insulin using side chain anchored lysine - Google Patents
Solid phase peptide synthesis of insulin using side chain anchored lysine Download PDFInfo
- Publication number
- WO2013156977A1 WO2013156977A1 PCT/IB2013/053111 IB2013053111W WO2013156977A1 WO 2013156977 A1 WO2013156977 A1 WO 2013156977A1 IB 2013053111 W IB2013053111 W IB 2013053111W WO 2013156977 A1 WO2013156977 A1 WO 2013156977A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- thr
- prl
- arg
- group
- resin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
- C07K1/042—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers characterised by the nature of the carrier
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- Insulin and insulin derivatives and analogs are prepared efficiently by the solid phase synthesis of the A and B-chains and the random oxidation of the bisoxidized A-chain with linear B-chain. Lysine and lysine containing peptides were attached through the lysine side chain on acid and thermo labile resins. This method allows the solid phase synthesis of various peptides and modified peptides.
- Insulin is a small protein which consists of two peptide chains, the A- and B-chains, which are joined together by two intermolecular disulfide bonds. In addition the A-chain contains an additional intramolecular disulfide bond. Insulin and its derivatives are the most important drugs for the treatment of diabetes. The pharmaceutical properties of insulin can be changed by slight modifications of the two peptide chains. Therefore several insulin derivatives (Figure 1) have been developed and commercialized such as insulin detemir (Levemir), insulin glargin (Lantus), insulin aspart (Novolog), insulin lispro (Humalog) and insulin glulisine (Apidra).
- the present application discloses effective methods to overcome the above cited problems thus enabling the chemical synthesis of insulin, its derivatives and its analogues.
- the present application discloses: 1) The synthesis of A chains; 2) B chains; and 3) the combination of the bis-oxidized A and B chains.
- a lysine-resin conjugate comprising a resin and a lysine or a lysine derivative of the formula I: wherein
- W is an acid sensitive or thermal sensitive resin, or a resin that is both acid and thermal sensitive toward cleavage of the lysine or lysine derivative from the resin;
- R is selected from the group consisting of -OH, a carboxyl protecting group, -NH 2 , -0-C i. ( , alkyl, -0-C 2-6 alkenyl, -O-tri-Ci-3 alkyl silyl, a peptide residue selected from the group consisting of -Pro-OH, -Pro-NH 2 , -Pro-0-C,. 6 alkyl, -Pro-0-C 2-6 alkenyl, -Pro-O-tri-C,., alkylsilyl.
- Prl is an -OH protecting group and each Pr2 and PR3 is independently hydrogen or a guanidine protecting group;
- P is hydrogen, an amino protecting group, an N-tenninus peptide residue comprising 1 to 200 amino acids comprising optionally protected side chain and optionally protected terminal amino group, wherein the N-terminus peptide residue comprises a C-terminus and an N-terminus, and a peptide residue selected from the group consisting of SEQ ID NOs: 1, 3, 4, 5, 6, 7, 8, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 and 36;
- R is selected from the group consisting of -OH, a carboxyl protecting group, -NH 2 , -0-Ci_6 alkyl, -0-C 2-6 alkenyl, -0-tri-Ci -3 alkyl silyl, a peptide residue selected from the group consisting of -Pro-OH, -Pro-NH 2 , -Pro-0-Ci. 6 alkyl, -Pro-0-C 2 _6 alkenyl, -Pro-0-tri-Ci.
- a peptide residue comprising 1 to 200 amino acids comprising optionally protected side chain and optionally protected terminal carboxyl group means that, where the peptide residue comprises one or more amino acids, each of the side chains of the amino acid may be independently unprotected or may be independently protected by a protecting group, and the carboxyl group may be a free carboxyl group (-COOH) or a protected carboxyl group.
- the resin is selected from the group consisting of 2-chlorotrityl resin, 4-methoxytrityl resin, 4-methyltrityl resin, tri-alkoxydiphenyl resin, tetra-alkoxydiphenyl resin, benzyl resin, methoxybenzyl resin, dimethoxybenzyl resin and trimethoxybenzyl resin.
- the resin W- comprises the formulae Ilia, nib, IIIc or Hid:
- the lysine-resin conjugate comprising the SEQ ID NOs as noted herein include the peptide residue comprising the lysine or lysine derivative that is attached to the resin and the lysine or lysine derivative may be located at the C-terminal, N-terminal or at an internal position of the peptide residue.
- P is selected from the group consisting of tert-butyloxycarbonyl (Boc), 9-fluorenylmethyloxycarbonyl ( Fmoc), benzyloxy-carbonyl (carboxybenzyl or Z), l-(4,4-dimethyl-2,6-dioxocyclohex-l-ylidene)-ethyl (Dde), 2-nitrophenylsulfenyl (Nps) and allyloxycarbonyl (alloc).
- P is selected from the group consisting of acetyl (Ac), Fmoc, 9-fluoreneacetyl group, 1 -fluorenecarboxylic group, 9- fluorenecarboxylic group, 9-fluorenone-l -carboxylie group, benzyloxycarbonyl, xanthyl (Xan), trityl (Trt), 4-methyltrityl (Mtt), 4-methoxytrityl (Mmt), 4-methoxy-2,3,6-trimethyl- bcnzenesulphonyl (Mtr), mesitylenc-2-sulphonyl (Mts), 4,4-dimethoxybenzhydryl (Mbh), tosyl (Tos), 2,2,5,7,8-pentamethyl chroman-6-sulphonyl (Pmc), 4-methylbenzyl ( McBzl), 4- methoxybenzyl (MeOBzl),
- a "peptide residue” or “peptide fragment” is a peptide having one or more amino acids.
- a peptide residue that is attached to the carboxyl terminus, such as that of the lysine-resin conjugate of the formula I, for example, may be a single amino acid that has an alpha- ami no protecting group or a carboxyl protecting group, or both protecting groups (i.e., protected or partially protected), or the amino acid lacks an amino protecting group or lacks a carboxyl protecting group (i.e., unprotected or partially protected) or the peptide residue may be dipeptide or polypeptide, wherein each of the amino acids in the peptide may be protected, partially protected or unprotected.
- R is -Oi l or is a peptide residue selected from the group consisting of proline (Pro), threonine (Thr) and thrconine-arginine-arginine (Thr-Arg-Arg), each protected, partially protected or unprotected.
- the -011 protecting group Prl is an alkyl or benzyl type protecting group such as tert-butyl, 4-tnethoxy benzyl etc.
- each Pr2 and Pr3 is independently a guanidine protecting group, a C 1-6 alkoxycarbonyl or arylsulfonyl type such as Pbf, Pmc etc.
- -OH is selected from the group consisting of -OH, a carboxyl protecting group, -NH 2 , -0-Ci -6 alkyl, -0-C 2- 6 alkenyl, -0-tri-Ci -3 alkyl silyl, a peptide residue selected from the group consisting of -Pro-OH, -Pro-NH 2 , -Pro-0-Ci -6 alkyl, -Pro-0-C 2 .
- Prl is hydrogen or a -OH protecting group and each Pr2 and PR3 is
- P is hydrogen, an amino protecting group, an N-terminus peptide residue comprising 1 to 200 amino acids comprising optionally protected side chain and optionally protected terminal amino group, wherein the N-terminus peptide residue comprises a C-terminus and an N-terminus, and a peptide residue selected from the group consisting of SEQ ID NOs: 1, 3, 4, 5, 6, 7, 8, 16,
- R is selected from the group consisting of -OH, a carboxyl protecting group, -NH 2 , -0-Ci_ 6 alkyl, -0-C 2-6 alkenyl, -0-tri-Ci -3 alkyl silyl, a peptide residue selected from the group consisting of -Pro-OH, -Pro-NH 2 , -Pro-O-Ci.6 alkyl, -Pro-0-C 2 _ 6 alkenyl, -Pro-0-tri-Ci -3 alkylsilyl, Thr(Prl), -Thr(Prl)-Arg(Pr2)-Arg(Pr3)-OH, -Thr(Prl)-Arg(Pr2)-Arg(Pr3)-NH 2 , - Thr(Prl)-Arg(Pr2)-Arg(Pr3)-0-Cl-6 alkyl, -Thr(Prl)-Arg(Pr2)-Arg(Pr3)-0-C 2 .
- R 1 is selected from the group consisting of -Pro-OH, -Pro-NH 2 , -Pro-()-Cu,alkyl, -Pro-0-C 2-6 alkenyl, -Pro-0-tri-Ci -3 alkylsilyl, Thr( Prl ), -Thr(Prl)-Arg(Pr2)-Arg(Pr3)-OH, - Thr(Prl)-Arg(Pr2)-Arg(Pr3)-NH 2 , -Thr(Prl)-Arg(Pr2)-Arg(Pr3)-0-Cl-6 alkyl, -Thr(Prl)- Arg(Pr2)-Arg(Pr3)-0-C 2-6 alkenyl, -Thr( r 1 )-Arg(Pr2 )- Arg(Pr3 )-0-tri-C , .3 alkylsilyl, -Thr(Prl)- OH, -Thr(Prl)-NH 2 , -Thr
- 3alkylsilyl or a C-terminus peptide residue comprising 1 to 200 amino acids comprising optionally protected side chain and optionally protected terminal carboxyl group;
- N-terminus peptide comprising 1 to 200 amino acids comprising optionally protected side chain and optionally protected terminal amino group, wherein the N-terminus peptide comprises a C-terminus and an N-terminus, to form the conjugate of the formula la:
- R and P are as defined above;
- the amino protecting group of the 1 to 200 amino acids comprising optionally protected side chain, such as Fmoc is removed by treatment with a secondary amine such as pipcridine or diethylamine and the free amine is further coupled with an optionally protected amino acid or an optionally protected peptide comprising 1 to 200 amino acids using a coupling agent such as DCC, DIG or ED AC, optionally in the presence of an additive selected from HOBt, HOSu, thiophenol or pentafluorophenol.
- the resin W- comprises a formula Ilia, Illb, IIIc or Hid, wherein the variables n, R 1 , R 2 , R 3 and Z are as defined above.
- the lysine or lysine derivative is selected from the group consisting of SEQ ID NOs: 1, 3, 4, 5, 6, 7, 8, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 and 36.
- step b') wherein the alpha-amino group of the lysine or lysine derivative is coupled with a N-terminus peptide residue comprising 1 to 200 amino acids is performed by activating the N-terminus free carboxyl group to form an activated carboxyl group using an activated group selected from the group consisting of DCC, PFPOH, DMAP; PFP-trifluoroacetate, pyridine; PFPOH, EDC, DMA; EDC, HOBt; FDPP, DIEA, DMF, EDC, HOAt; HBTU; HATU; HATU, HOAt; Ac 2 0, DMAP; Ac 2 0, pyridine; DPPA; FDPP; DCC, HOAt; DCC, HOBt; DIC, HOBt; and EDC-HC1; and condensing the activated carboxyl group of the N-terminus peptide to form the conjugate of the formula la, wherein P is an N-terminus peptide residue comprising
- the clause " R is a C-terminus peptide residue comprising 1-200 amino acids” means that the 1-200 amino acids is attached to the C-terminus of the lysine or lysine derivative.
- the clause "P is an N-terminus peptide residue comprising 1-200 amino acids” means that the 1-200 amino acids is attached to the N-terminus (or the alpha-amino group) of the lysine or lysine derivative.
- the activation of the C-terminus free carboxyl group is performed in a solvent selected from the group consisting of DCM, DMF, NMP, DMSO or mixtures thereof.
- step b) or b') the method furt her comprising: d) cleaving the peptide residue from the resin W by contacting the resin-bound peptide conjugate of formula la under mild acidic condition using a mixture of an organic acid and a solvent, or by heating the resin-bound peptide to an elevated temperature, or both using a mixture of an organic acid and a solvent, along with heating the resin-bound peptide at an elevated temperature for a sufficient period of time to cleave the peptide comprising a lysine with a free amino group from the resin W; e) acylating the free amino group of the lysine comprising peptide with R'CO-X where X is CI, Br, CH 3 CO- and R' is selected from the group consisting of CH 3 CO- or a C -terminus carboxyl activated peptide residue comprising 1 to 200 amino acids to form an N-acylated peptide derivative; and h
- the acyl group (R'CO-) is derived from the acyl halide or anhydride of myristic acid, a coded or uncoded amino acid halide, Fmoc-Glu-OtBu and tBuO-CO-(CH 2 )i 4 -CO-NH-Glu-OtBu.
- the lysine-i esin conjugate of the formula la comprising a C-terminus free carboxyl group is further converted to the corresponding alkyl carboxyl ester by contacting the carboxyl group with an alkyl halide selected from the group consisting of diphenylmethyl chloride, 4-methoxydiphcnyImethyl chloride, 4-methyldiphenylmethyl chloride, trityl chloride, 2-chlorotrityl chloride, 4-methyltrityl chloride and trimethylsilyl chloride and triethylsilyl chloride in the presence of a base, or by activating the C -terminal carboxyl group and reacting with an amino resin selected from Rink- amide MBHA or Rink-amide AM resin.
- an alkyl halide selected from the group consisting of diphenylmethyl chloride, 4-methoxydiphcnyImethyl chloride, 4-methyldiphenylmethyl chloride, trityl chloride, 2-chlorot
- the C-terminus peptide comprising 1 to 200 amino acids, or the N-terminus peptide residue comprising 1 to 200 amino acids is selected from a protected, partially protected or unprotected insulin B-chain or an insulin B-chain derivative, or is a peptide residue selected from SEQ ID NOs: 1 , 3, 4, 5, 6, 7, 8, 16, 1 7. 18, 19, 20, 2 1 , 22, 23, 24, 25, 26, 27, 28. 29, 30, 31 , 32, 33, 34, 35 and 36.
- the acyl group ( R'CO-) is derived from the halide or anhydride of myristic acid, a coded or uncoded amino acid halide, Fmoc-Glu-OtBu and tBuO- CO-(CH 2 )i4-CO-NH-Glu-OtBu.
- the lysine-resin conjugate of the formula la comprising a C-terminus free carboxyl group is further converted to the corresponding alkyl carboxyl ester by contacting the carboxyl group with an alkyl halide selected from the group consisting of diphenylmethyl chloride, 4-methoxydiphenylmethyl chloride, 4- methyldiphenylmethyl chloride, trityl chloride, 2-chlorotrityl chloride, 4-methyltrityl chloride and trimethylsilyl chloride and triethylsilyl chloride in the presence of a base, or by activating the C- terminal carboxyl group and reacting with an amino resin selected from Rink-amide MBHA or Rink-amide AM resin.
- an alkyl halide selected from the group consisting of diphenylmethyl chloride, 4-methoxydiphenylmethyl chloride, 4- methyldiphenylmethyl chloride, trityl chloride, 2-chlorotrityl chloride, 4-
- the base is diisopropylethyl amine.
- Rink-amide MBHA and Rink-amide AM resin is known in the art. See Boussard, Cyrille et al. European Journal of Medicinal Chemistry, 37(11), 2002, pp.883-890; Rink-amide AM resin is also known as 4-(2',4'- dimethoxyphenyl-Fmoc-aminomethul)phenoxyacetamidoaminomethyl resin.
- the method further comprising: concurrent oxidizing and cleaving the peptide from the resin of an A-chain peptide-resin of SEQ ID NO: 9 following by deprotection to form the bis-oxidized deprotected bisoxidized insulin A chain of SEQ ID NO: 14; and combining the bisoxidized insulin A chain of SEQ ID NO: 14 with a B-chain of SEQ ID NO: 27 to form an insulin analog of SEQ ID NO:6; or combining the bisoxidized insulin A chain of SEQ ID NO: 14 with a B-chain of SEQ ID NO: 29 to form an insulin analog of SEQ ID NO:8; or combining the bisoxidized insulin A chain of SEQ ID NO: 36 with a B-chain of SEQ ID NO: 23 to form an insulin analog of SEQ ID NO:4.
- a method for the solid phase synthesis of a protected, partially protected or unprotected insulin B-chain or an insulin B-chain derivative comprising: preparing a lysine-resin conjugate comprising a resin and a lysine or a lysine derivative of the formu
- n, R 1 , R 2 and R 3 , and Z are as defined above;
- R is selected from the group consisting of -OH, a carboxyl protecting group, -NH 2 , -0-Ci -6 alkyl, -0-C 2 -6 alkenyl, -0-tri-Ci -3 alkyl silyl, a peptide residue selected from the group consisting of -Pro-OH, -Pro-NH 2 , -Pro-0-C 1-6 alkyl, -Pro-0-C 2-6 alkenyl, -Pro-0-tri-C,- 3 alkylsilyl, Thr(Prl), -Thr(Prl)-Arg(Pr2)-Arg(Pr3)-OH, -Thr(Prl)-Arg(Pr2)-Arg(Pr3)-NH 2 , -Thr(Prl)-Arg(Pr2)- Arg(Pr3)-0-Cl-6 alkyl.
- Prl is hydrogen or a -OH protecting group and each Pr2 and PR3 is
- P is hydrogen, an amino protecting group, an N-terminus peptide residue comprising 1 to 200 amino acids comprising optionally protected side chain and optionally protected terminal amino group, wherein the N-terminus peptide residue comprises a C-terminus and an N-terminus; provided that when R is selected from the group consisting of -Oi l, a carboxyl protecting group, -Nil:, -O-C 1.
- alkyl silyl a peptide residue selected from the group consisting of -Pro-OH, -Pro-NH 2 , -Pro-0-Ci -b alkyl, -Pro-0-C 2- 6 alkenyl, -Pro-O-tri-Ci-3 alkylsilyl, Thr(Prl), -Thr(Prl)-Arg(Pr2)-Arg(Pr3)-OH, -ThrfPrl )-Arg(Pr2)-Arg(Pr3)-NI I 2 , - Thr( Prl )-Arg(Pr2)-Arg(Pr3)-0-C 1 -6 alkyl.
- the peptide residue lb is the peptide residue sequence identity as disclosed in the present application that comprises the sequence identity of the protected, partially protected or unprotected insulin B-chain or an insulin B-chain derivative.
- the protected, partially protected or unprotected insulin B-chain or an insulin B-chain derivative is selected from the group consisting of a des- Thr(30) insulin B-chain analog, a B-chain of insulin detemir (insulin levemir), an insulin degludec, an insulin Lispro ( Humalog), an insulin glarginc ( Lantus), an insulin aspart (Novolog), and analogs or derivatives thereof.
- the resin is a 2-chlorotrityl resin.
- P is selected from the group consisting of tcrt-butyloxycarbonyl (Boc), 9- fluorenylmethyloxycarbonyl (Fmoc), benzyloxy-carbonyl (carboxybenzyl or Z), 1 -(4,4-dimethyl- 2,6-dioxocyclohex-l-ylidene)-ethyl (Dde), 2-nitrophenylsulfenyl (Nps) and allyloxycarbonyl (alloc).
- the partially protected or unprotected insulin B -chain or an insulin B-chain derivative is selected from the group consisting of SEQ ID NOs: 4, 5, 6, 7 and 8, and analogs or derivatives thereof; and further cleaving of the resin-bound insulin B-chain or an insulin B-chain derivative by contacting the resin-bound peptide under mild acidic condition using a mixture of an organic acid and an alcoholic solvent, or by heating the resin-bound peptide to an elevated temperature, or both using a mixture of an organic acid and an alcoholic solvent along with heating the resin-bound peptide at an elevated temperature for a sufficient period of time to cleave the insulin B-chain or an insulin B-chain derivative from the resin.
- the organic acid is selected from the group consisting of trifluoroacetic acid and acetic acid, and mixtures thereof
- the alcoholic solvent is selected from the group consisting of trifluoroethanol, hexafluoro-isopropanol, methanol and mixtures thereof, and heating of the resin bound peptide is performed with microwaves.
- the partially protected or unprotected insulin B-chain or an insulin B-chain derivative is selected from the group consisting of an N-acylated derivative, a pegylated derivative, a biotinylated derivative, a derivative comprising a chromophore and a peptide residue comprising a natural amino acid residue, an unnatural amino acid residue, and mixtures thereof.
- a method for the solid phase synthesis of a protected, partially protected or unprotected insulin A-chain or an insulin A-chain derivative comprising: preparing a peptide-resin conjugate comprising a resin and a peptide residue, wherein the peptide-resin conjugate comprises a formula I, wherein:
- R is selected from the group consisting of -OH, a carboxyl protecting group, -NH 2 , -0-C 1-6 alkyl, -0-C 2 -6 alkenyl, -0-tri-Ci -3 alkyl silyl, a peptide residue selected from the group consisting of -Pro-OH, -Pro-NH 2 , -Pro-0-Ci -6 alkyl, -Pro-0-C 2-6 alkenyl, -Pro-0-tri-Ci -3 alkylsilyl, Thr(Prl), -Thr(Prl)-Arg(Pr2)-Arg(Pr3)-OH, -Thr(Prl)-Arg(Pr2)-Arg(Pr3)-NH 2 , -Thr(Prl)-Arg(Pr2)- Arg(Pr3)-0-Cl-6 alkyl, -Thr(Prl)-Arg(Pr2)-Arg(Pr3)-0-Cl-6 alkyl, -Thr(
- n, R 1 R 2 , R 3 and Z are as defined above; and wherein the peptide residue is a protected, partially protected or unprotected insulin A-chain or an insulin A-chain derivative, or is a peptide residue selected from SEQ ID NOs: 9, 10, 1 1 , 12, 13, 14, 1 5 or mixture thereof;
- the method comprising contacting the peptide-resin conjugate with oxidizing agent to simultaneously oxidize the insulin A-chain and cleave the peptide residue from the resin; globally deprotecting the protected bis-oxidized insulin A-chain; and purifying the unprotected bis- oxidized insulin A-chain.
- the method further comprises contacting the unprotected bis-oxidized insulin A-chain with an insulin B-chain peptide selected from SEQ ID NOs: 3, 23, 27, 29 and 34 to form an animal or human insulin or insulin analog.
- the animal or human insulin or insulin analog is selected from SEQ ID NOs: 1, 4, 5, 6, 7 and 8, and insulin glulisine (Adipra).
- an insulin B-chain peptide selected from SEQ ID NOs: 3, 23, 27, 29 and 34 comprising cleaving the peptide from a peptide-resin conjugate of the formula IV:
- W is a resin of a formulae Ilia, Illb, IIIc or llld wherein n, R 1 R 2 and R 3 and Z are as defined above, wherein:
- the peptide-resin conjugate is selected from the group consisting of SEQ ID NOs: 16, 17, 18, 20, 22 and 24.
- the peptide-resin conjugate is selected from SEQ ID NOs. 16 or 17 is further deprotected to form human B-chain of SEQ ID NO: 3.
- the organic acid is selected from the group consisting of trifluoroacetic acid and acetic acid, and mixtures thereof
- the alcoholic solvent is selected from the group consisting of trifluoroethanol, hexafluoro-isopropanol, methanol and mixtures thereof, and heating of the peptide-resin conjugate is performed at about 30 to 50 °C.
- the cleavage of the resin-bound peptide is performed by heating the resin-bound peptide at an elevated temperature in an alcoholic solvent with the intermittent addition of about 0.01 wt/wt%, 0.02 wt/wt%, 0.03 wt/wt%, 0.05 wt/wt%, 0.1 wt/wt%, 0.2 wt/wt%, 0.5 wt/wt%, 1.0 wt/wt%, 2.0 wt/wt%, 3.0 wt/wt%, 4.0 wt/wt% or about 5.0 wt/wt% of the organic acid.
- the acid may be added at intervals of about 5 minutes, 10 minutes, 15 minutes, 30 minutes or about 1 hour.
- heating the resin-bound peptide is performed at an elevated temperature of about 25 - 30 °C, 30 - 35 °C or 35 - 40 °C.
- the cleavage may be enhanced with an additive that accelerates coupling reactions in peptide synthesis selected from hydroxybenzotriazol, hydroxysuccinimide, pentafluorophenol and thiophenol.
- the partially protected or unprotected insulin B-chain or an insulin B-chain derivative is selected from the group consisting of an N-acylated derivative, a pegylated derivative, a biotinylated derivative, a derivative comprising a chromophore and a peptide residue comprising a natural amino acid residue, an unnatural amino acid residue, and mixtures thereof.
- the derivative is a variant of the insulin B-chain or insulin B-chain derivative.
- peptide synthesis when the peptide is cleaved from the resin, further peptide synthesis may be performed by solution peptide synthesis, solid phase peptide synthesis or a combination of solution and solid phase peptide synthesis, also referred to as phase change synthesis.
- a lysine has an amine side chain, a alpha-amino group and a carboxyl group, peptide coupling reactions with a lysine, that may be attached to the resin by the side chain or by the carboxyl group, there are multiple permutations for peptide synthesis (solid phase or solution phase) to prepare linear and/or branched peptides.
- further solution phase peptide synthesis may include various combinations of the steps of: 1) Protecting the free amine group of the lysine side chain; 2) deprotccting the C- terminal carboxyl group and coupling of the free carboxyl group with an amino acid or peptide fragment, or derivatives thereof; 3 ) deprotecling the C-terminal carboxyl group and attaching the free carboxyl group to the resin and further performing solid phase peptide synthesis by peptide coupling to the N-terminal or peptide coupling to the amine side chain of the lysine (to prepare branched peptides); 4) deprotccting the N-terminal amino group (alpha-amino group) and coupling of the free amine with an amino acid or peptide fragment; and 5) combinations thereof.
- an "acid sensitive” resin, a “thermal sensitive” resin or both an “acid and thermal sensitive” resin is a resin, such as the resin in the lysine resin-conjugate, that detaches from the lysine or lysine derivative under mild acidic conditions, under relatively low
- branched peptide is a peptide that may be prepared according to the methods described herein, wherein amino acids or peptide residues may be attached to 1) the amino-side chain of a lysine group, 2) the C-terminal carboxyl group, and 3) the N-terminal amino group.
- global deprotection means that under certain deprotccting conditions, such as a strongly acidic acid condition, the condition result in the deprotection of all protecting groups of the lysine derivative or peptide on the resin.
- the peptide residue comprising 1 to 200 optionally protected amino acids comprise an amino protecting group P on the amino acid, wherein each P on the amino acid residue is hydrogen (i.e., unprotected) or is independently selected from the group consisting of t ert- butyl ox yc arbonyl (Boc), 9- fluorenylmethyloxycarbonyl (Fmoc), benzyloxy-carbonyl (carboxybenzyl or Z), 1 -(4,4-dimethyl- 2,6-dioxocyclohex- 1 -yl idene)-ethyl (Dde), 2-nitrophenylsulfenyl (Nps) and allyloxycarbonyl (alloc).
- each P on the amino acid residue is hydrogen (i.e., unprotected) or is independently selected from the group consisting of t ert- butyl ox yc arbonyl (Boc), 9- fluorenylmethyl
- peptide residue comprising a single amino acid or a peptide residue, and wherein each amino group and each carboxyl group of the peptide residue may be independently protected or unprotected.
- the peptide residue or peptide fragment contains at least 2 amino acid residues, at least 10 amino acid residues or at least 200 amino acid residues.
- a "carboxyl protecting group” for example, as represented in the compound of the formula I, means that the group that is attached to -C(O)- group includes the oxygen of the -C(O)- group and further comprises the protecting group as known in the art and as described herein.
- a comprehensive list of suitable protecting groups may be found in T. W. Greene, Protecting Groups in Organic Synthesis, 3rd edition, John Wiley & Sons, Inc. 1999.
- a "variant" means a peptide substantially homologous to a native peptide or derivative, but which has one or more amino acid sequence that is different from the native peptide or peptide derivative that are based one or more deletions, insertions or substitutions.
- Amino acid sequence insertions include amino- and/or carboxyl-terminal fusions ranging in length from one residue to peptides containing a ten, twenty or thirty or more residues, as well as intrasequence insertions of single or multiple amino acid residues. Intrasequence insertions, that is, insertions within the desired polypeptide sequence, may range generally from about 1 to 10 residues, 1 to 5 or 1 to 3 residues.
- Variants can comprise conservatively substituted sequences, meaning that a given amino acid residue is replaced by a residue having similar physiochemical characteristics. See, Zubay, Biochemistry, Addison-Wesley Pub. Co., (1983). It is a well- established that certain amino acids substitutions, i.e., "conservative" amino acid substitutions, can frequently be made in a protein or a peptide without altering either the confirmation or the function of the protein or peptide.
- Such changes include substituting any of isoleucine (I), valine (V), and leucine (L) for any other of these amino acids; aspartic acid (D) for glutamic acid (E) and vice versa; glutamine (Q) for asparagine (N) and vice versa; and serine (S) for threonine (T) and vice versa.
- Variants will have an amino acid sequence having at least 90% amino acid sequence identity with the reference sequence, at least 95%, at least 97%, at least 98% or at least 99% amino acid sequence identity. The variants will retain the primary function of the parent from which it they are derived.
- Figure 1 shows the sequence of human insulin and various derivatives
- Figure 2 is a representative process scheme for a solid phase synthesis of bisoxidized human insulin A-chain isomers.
- Figure 3 is a representative scheme showing a step-by-step solid-phase synthesis of the insulin B-chain using a CTC-resin.
- Figure 4 is a representative scheme showing the synthesis of an insulin B-Chain using Fmoc- Lys-Thr( t Bu )-OH attached through the side chain of Lys on an MMT-resin.
- Figure 5 is a representative scheme for the solid-phase synthesis of Fmoc-Lys-Thr(tBu)- Arg(Pbf)-Arg(Pbf)-OI I (SEQ ID NO: 19) for Glargin B-Chain.
- Figure 6 is a representative scheme for the synthesis of insulin Glargin B-Chain using Fmoc-Lys-Thr(tBu)-Arg(Pbf)-Arg(Pbf)-OH attached through the side chain of Lys on a MMT- resin.
- Figure 7 is a representative scheme for the synthesis of insulin Detemir B-chain with N- terminal protection and using Fmoc- Lys attached through the side chain onto a MMT-resin.
- Figure 8 is a representative scheme for the synthesis of insulin Degludec B-Chain using Fmoc- Lys attached through the side chain on MMT-resin.
- Figure 9 is a representative scheme for the synthesis of insulin Degludec B-chain using N- terminal protection.
- Figure 10 is a representative scheme for the synthesis of biotinylated insulin B-chain.
- Figure 11 is a representative scheme for the synthesis of insulin and insulin analogs (Lispro and Aspart) by chain combination.
- Figure 12 is a representative scheme for the chain combination of an insulin analogs (Detemir and Degludec).
- Figure 13 is a representative scheme for the chain combination of an insulin analog Glargin.
- a method for the solid-phase synthesis of the insulin bis-oxidized A-chain in which the cleavage of the protected peptide from the resin and its oxidation proceeds concurrently and in a short period of time.
- this method the synthetic problem due to the insolubility of the A-chain is overcome.
- this is achieved by applying solid-phase-synthesis using acid labile resins.
- acid labile resins include the trityl, diphenylmethyl and benzyl-type.
- the peptide chain is assembled using standard protocols for the solid phase synthesis of peptides using, for example, Fmoc-amino acids ( Figure 2).
- Oxidation of the resin-bound peptide maybe performed using iodine under mild acidic conditions, such as in halogenated hydrocarbons. Under these conditions, the cleavage of the protected peptide from the resin proceeds concurrently with the oxidation reaction, and the precipitation of the A-chain is avoided.
- solutions of trifluoroacetic acid or acetic acid in dichloromethane that are mixed with alcohols, such as trifluoroethanol or methanol were used as the solvent for the concurrent oxidation and cleavage from the resin.
- 2-chlorotrityl resin was used for the solid-phase chain assembly of the protected A-chain.
- the bis-oxidized protected linear A-chain that was obtained was deprotected by contacting the A-chain with various acidic solvent solutions, including DCM, TFA, TES and thioethers, and mixtures thereof.
- various acidic solvent solutions including DCM, TFA, TES and thioethers, and mixtures thereof.
- the present application discloses all three expected isomers of the bis-oxidized insulin A-chain ( Figure 2).
- the isomers can be separated by HPLC but can be also isolated and purified as a mixture of isomers.
- the present application discloses a synthesis of the insulin B-chain in a step-by-step manner on acid sensitive resins of the trityl-type, such as the 2-chlorotrityl resin ( Figure 3).
- acid sensitive resins of the trityl-type such as the 2-chlorotrityl resin ( Figure 3).
- Fmoc-amino acids suitably protected at their side chains with acid sensitive groups was also employed.
- the present application also discloses the synthesis of insulin B-chain peptides and its derivatives such as the des-Thr(B30) insulin B-chain may be prepared where the side chain of Lys(B29) is attached to the resin instead of the chain's carboxyl group ( Figures 4).
- the B-chain for Glargin may be synthesized either by solid phase attachment of the protected arginine through the carboxyl group ( Figure 5) or using side group attachment through the lysine ( Figure 6).
- the side chain of the lysine that is attached to the resin may be used to prepare the Insulin Detemir B-chain (Figure 7), and Insulin Degludec B Chain ( Figure 8, 9).
- the present application further discloses that if the resin used for the side chain attachment of Lys is relatively labile, such as the 2-chlorotrityl resin or the 4-methoxytrityl resin, the partially protected insulin B-chain can be readily obtained by mild acidic or thermal treatment of the resin-bound peptide, where the peptide is cleaved from the resin with selectively deprotected Lys side-chain amino function.
- the partially deprotected insulin B-chains, their shorter or longer fragments and derivatives, can be selectively acylated in solution at the lysine side chain providing a variety of important B-chain derivatives.
- the present application further discloses the synthesis of Lys(15-myristoyl)-des-Thr(30) human insulin B-chain, the synthesis of Lys(15-carboxypentadecanoyl-y-glutamyl)B(29)-des- Thr(B30) human insulin B-chain and the selective pegylation and biotinylation (Figure 11) of the side chain of Lys(B29) as well as the solid-phase-synthesis of selectively at the Lys(B29) side chain branched Insulin B-chain peptides.
- the present application also discloses the selective acylation of the side chain of the Lys(B29)-human insulin B-chain and its shorter and longer peptide analogues and their derivatives. This can be performed by preparing and isolating the insulin B-chain protected at its amino terminal function by the Fmoc-group or a Z-type group. After the removal of the side chain protecting groups of the insulin B-chain derivative, the free amino function of the
- Lys(B30)-insulin may be acylated.
- the present appliction further discloses that the combination of the insulin chains using the bisoxidized A-chain of human or animal insulin and their derivatives, with the B-chain o f human or animal insulin and their derivatives proceed smoothly in aqueous solutions buffered with the addition of various salts, such as sodium, calcium, zinc, iron salts etc.
- the solution may contain organic solvents such as alcohols, DMSO, acetonitrile etc. at various pH, including at pH > 7, and at different temperatures, including from about 0-5 °C, 2-6 °C and 5- 10 °C.
- the bis-oxidized A-chain and the B-chain can be reacted at different ratios, such as a ratio where the A-chain/B-chain ratio is >1 , such as 1.05: 1, 1.1 : 1 , 1.2: 1, 1.3: 1 , 1.5: 1 and 2: 1 .
- the reaction provides a mixture of mono-oxidized A-chain, oxidized B-chain and B-chain dimers, A-chain dimmers and mixtures thereof.
- the product mixture may be separated by HPLC and recycled after the oxidation of the mixture of mono and di-oxidized A-chain, or converted to different insulin products by equilibrating with a redox system such as cysteine cysteine, or oxidized and reduced glutathione etc.
- combination yields of > 60% may be obtained.
- a mild oxidant is added to the combination mixture, such as DMSO or the redox mixture oxidized and reduced glutathione, to re-oxidize the A-chain.
- a mild reducing agent such as thiols, including thiolamine, dithiotreitol or a redox system, may be added.
- the total yield of insulin and insulin analogs may be improved by 5-25% ( Figures 1 1-13).
- the remaining active sites of 2-CTC resin were neutralised by adding 10 mL of methanol (MeOH) and reacting for 1 hour.
- the resin was filtered and washed twice with 400 mL DMF.
- the resin was filtered and treated twice with 500 mL 25% by volume of piperidine in DMF for 30 min.
- the resin was washed four times with 500 mL DMF.
- the resin was unswelled with 3 washes with 500 mL of isopropanol (IP A); and dried to constant weight. 70-95% of the mmol of the used amino acid was bound on the resin.
- MBH-Br resin 100 g; 190 mmol was placed in a 2 L peptide synthesizer and swollen with 700 mL DCM for 30 min at 25 °C. The resin was filtered and then a solution of Fmoc-amino acid and DIEA in 500 mL DCM was added. The mixture was stirred under nitrogen for 6 h at 25 °C. Then the remaining active sites of the MBH resin were bound by adding 10 mL MeOH and stirring for 24 h. The resin was then filtered and washed twice with 400 mL DMF. The resin was filtered and reacted twice with 500 mL of a solution of 25% by volume of piperidine in DMF for 30 min.
- the resin was then washed four times with 500 mL DMF.
- the resin was diswelled with three washes with 500 mL IPA.
- the resin was then dried to constant weight under vacuum (15 torr, 25 °C). 60-90% of the mmol of the used amino acid were bound onto the resin.
- the resin was placed in a 15 ml reactor and treated twice with 7 mL NMP, followed by filtration.
- Fmoc-amino acids were used for coupling of the individual amino acid or amino acid fragments: Fmoc-Gly-OH, Fmoc-Ala-OIl, Fmoc- Val-OI I, Fmoc-Ilc-OIl, Fmoc-Leu- OH, Fmoc-Phe-OH, Fmoc-Pro-OH, Fmoc-Asp(tBu)-OH, Fmoc-Glu(tBu)-OH, Fmoc-Lys(Boc)- OH, Fmoc-Lys(Mmt)-OH.
- C General method for the cleavage from the CTC- resin of the partially protected insulin peptides and of their protected fragments which contain Fmoc- or Boc-groups on their N-terminus and are selectively deprotected at a lysine side chain.
- the resulting mixture was stirred for 5 min at 0 °C and filtered (instead of 1% TFA the same volume of a mixture of dichloromethane/acetic acid/trifluoroethanol can be used with similar results).
- the resin was then washed three times with 10 mL DCM.
- the combined filtrates were heated to 15 °C and stirred for further 30 min.
- Pyridine was then added to the filtrates (1.3 equiv. relative to TFA) to neutralize TFA.
- the cleavage solution in DCM was then mixed with an equal volume of 3%-sodium thiosulphate in water in order to remove the excess iodine. This was indicated by the discoloration of the mixture.
- the resulting mixture was distilled at low pressure to remove DCM (350 torr at 28 °C).
- the resulting peptide or peptide fragment precipitated out after the removal of DCM.
- the resulting peptide was washed with water and dried at 30-35 °C under vacuum of 15 Torr.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Polyamides (AREA)
Abstract
Description
Claims
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/395,313 US20160031962A1 (en) | 2012-04-20 | 2012-04-20 | Solid phase peptide synthesis of insulin using side chain achored lysine |
NZ631001A NZ631001A (en) | 2012-04-20 | 2013-04-19 | Solid phase peptide synthesis of insulin using side chain anchored lysine |
BR112014026077-0A BR112014026077B1 (en) | 2012-04-20 | 2013-04-19 | METHOD OF SOLID PHASE SYNTHESIS OF A PROTECTED, PARTIALLY PROTECTED OR UNPROTECTED INSULIN B CHAIN OR AN INSULIN B CHAIN DERIVATIVE, AND METHOD FOR PREPARING AN INSULIN B CHAIN PEPTIDE |
CA2870891A CA2870891C (en) | 2012-04-20 | 2013-04-19 | Solid phase peptide synthesis of insulin using side chain anchored lysine |
CN201380031205.XA CN104428314B (en) | 2012-04-20 | 2013-04-19 | Solid phase peptide synthesis of insulin using side chain anchored lysine |
EP13726299.4A EP2838915B1 (en) | 2012-04-20 | 2013-04-19 | Solid phase peptide synthesis of insulin using side chain anchored lysine |
AU2013250755A AU2013250755B2 (en) | 2012-04-20 | 2013-04-19 | Solid phase peptide synthesis of insulin using side chain anchored lysine |
IL235183A IL235183B (en) | 2012-04-20 | 2014-10-19 | Solid phase peptide synthesis of insulin using side chain anchored lysine |
IN9089DEN2014 IN2014DN09089A (en) | 2012-04-20 | 2014-10-30 | |
HK15104038.9A HK1203525A1 (en) | 2012-04-20 | 2015-04-27 | Solid phase peptide synthesis of insulin using side chain anchored lysine |
US17/349,578 US20210388051A1 (en) | 2012-04-20 | 2021-06-16 | Solid phase peptide synthesis of insulin using side chain anchored lysine |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261636193P | 2012-04-20 | 2012-04-20 | |
US61/636,193 | 2012-04-20 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14395313 A-371-Of-International | 2014-11-20 | ||
US17/349,578 Division US20210388051A1 (en) | 2012-04-20 | 2021-06-16 | Solid phase peptide synthesis of insulin using side chain anchored lysine |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013156977A1 true WO2013156977A1 (en) | 2013-10-24 |
Family
ID=48539334
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2013/053111 WO2013156977A1 (en) | 2012-04-20 | 2013-04-19 | Solid phase peptide synthesis of insulin using side chain anchored lysine |
Country Status (10)
Country | Link |
---|---|
US (2) | US20160031962A1 (en) |
EP (1) | EP2838915B1 (en) |
CN (1) | CN104428314B (en) |
BR (1) | BR112014026077B1 (en) |
CA (1) | CA2870891C (en) |
HK (1) | HK1203525A1 (en) |
IL (1) | IL235183B (en) |
IN (1) | IN2014DN09089A (en) |
NZ (1) | NZ631001A (en) |
WO (1) | WO2013156977A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018108154A1 (en) | 2016-12-16 | 2018-06-21 | 中国医学科学院医药生物技术研究所 | Polymyxin derivative, preparation method and application thereof |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106432472B (en) * | 2016-10-24 | 2020-01-03 | 合肥国肽生物科技有限公司 | Solid-phase synthesis method of insulin |
JP2021521230A (en) * | 2018-04-16 | 2021-08-26 | ユニヴァーシティー オブ ユタ リサーチ ファウンデーション | Glucose-responsive insulin |
CN111518009B (en) * | 2019-02-01 | 2023-06-23 | 鲁南制药集团股份有限公司 | Fatty acid derivative and synthesis method thereof |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6562942B1 (en) * | 1999-02-23 | 2003-05-13 | Neurocrine Biosciences, Inc. | Methods for treatment of diabetes using peptide analogues of insulin |
WO2004052916A2 (en) * | 2002-12-06 | 2004-06-24 | Adaptive Therapeutics, Inc. | Novel cyclic peptides comprising cis-3 aminocycloalkanecarboxylic acids |
WO2006082204A1 (en) * | 2005-02-02 | 2006-08-10 | Novo Nordisk A/S | Insulin derivatives |
WO2008040536A1 (en) * | 2006-10-05 | 2008-04-10 | Lonza Ag | Method for peptide synthesis |
WO2008109079A2 (en) * | 2007-03-01 | 2008-09-12 | Novetide, Ltd. | High purity peptides |
WO2011042762A2 (en) * | 2009-10-08 | 2011-04-14 | Chemical & Biopharmaceutical Laboratories Of Patras Sa | Insulin like peptides |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2264065B1 (en) * | 2003-08-05 | 2017-03-08 | Novo Nordisk A/S | Novel insulin derivatives |
EP2424888A2 (en) * | 2009-05-01 | 2012-03-07 | F. Hoffmann-La Roche AG | Insulinotropic peptide synthesis using solid and solution phase combination techniques |
-
2012
- 2012-04-20 US US14/395,313 patent/US20160031962A1/en not_active Abandoned
-
2013
- 2013-04-19 WO PCT/IB2013/053111 patent/WO2013156977A1/en active Application Filing
- 2013-04-19 BR BR112014026077-0A patent/BR112014026077B1/en active IP Right Grant
- 2013-04-19 NZ NZ631001A patent/NZ631001A/en unknown
- 2013-04-19 CN CN201380031205.XA patent/CN104428314B/en active Active
- 2013-04-19 CA CA2870891A patent/CA2870891C/en active Active
- 2013-04-19 EP EP13726299.4A patent/EP2838915B1/en active Active
-
2014
- 2014-10-19 IL IL235183A patent/IL235183B/en active IP Right Grant
- 2014-10-30 IN IN9089DEN2014 patent/IN2014DN09089A/en unknown
-
2015
- 2015-04-27 HK HK15104038.9A patent/HK1203525A1/en unknown
-
2021
- 2021-06-16 US US17/349,578 patent/US20210388051A1/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6562942B1 (en) * | 1999-02-23 | 2003-05-13 | Neurocrine Biosciences, Inc. | Methods for treatment of diabetes using peptide analogues of insulin |
WO2004052916A2 (en) * | 2002-12-06 | 2004-06-24 | Adaptive Therapeutics, Inc. | Novel cyclic peptides comprising cis-3 aminocycloalkanecarboxylic acids |
WO2006082204A1 (en) * | 2005-02-02 | 2006-08-10 | Novo Nordisk A/S | Insulin derivatives |
WO2008040536A1 (en) * | 2006-10-05 | 2008-04-10 | Lonza Ag | Method for peptide synthesis |
WO2008109079A2 (en) * | 2007-03-01 | 2008-09-12 | Novetide, Ltd. | High purity peptides |
WO2011042762A2 (en) * | 2009-10-08 | 2011-04-14 | Chemical & Biopharmaceutical Laboratories Of Patras Sa | Insulin like peptides |
Non-Patent Citations (12)
Title |
---|
ALSINA J ET AL: "Solid-phase synthesis of ''head-to-tail'' cyclic peptides via lysine side-chain anchoring", TETRAHEDRON LETTERS, PERGAMON, vol. 35, no. 51, 19 December 1994 (1994-12-19), pages 9633 - 9636, XP026620291, ISSN: 0040-4039, [retrieved on 19941219], DOI: 10.1016/0040-4039(94)88531-1 * |
ALSINA JORDI ET AL: "Solid-phase synthesis of C-terminal modified peptides", BIOPOLYMERS, JOHN WILEY & SONS, INC, US, vol. 71, no. 4, 1 January 2003 (2003-01-01), pages 454 - 477, XP002468782, ISSN: 0006-3525, DOI: 10.1002/BIP.10492 * |
B. DUE LARSEN; A. HOLM J., PEPTIDE RES., vol. 52, 1998, pages 470 - 476 |
BELGI A ET AL: "The chemical synthesis of insulin: From the past to the present", IMMUNOLOGY, ENDOCRINE AND METABOLIC AGENTS IN MEDICINAL CHEMISTRY 2011 BENTHAM SCIENCE PUBLISHERS B.V. NLD, vol. 11, no. 1, 2011, pages 40 - 47, XP008164062, ISSN: 1871-5222 * |
BERNHARDT A ET AL: "THE SOLID-PHASE SYNTHESIS OF SIDE-CHAIN-PHOSPHORYLATED PEPTIDE-4-NITROANILIDES", JOURNAL OF PEPTIDE RESEARCH, BLACKWELL PUBLISHING LTD, OXFORD; GB, vol. 50, no. 2, 1 August 1997 (1997-08-01), pages 143 - 152, XP000659212, ISSN: 1397-002X * |
BOUSSARD, CYRILLE ET AL., EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 37, no. 11, 2002, pages 883 - 890 |
MEIENHOFER J ET AL: "SOLID-PHASE SYNTHESIS WITH ATTACHMENT OF PEPTIDE TO RESIN THROUGH AN AMINO ACID SIDE CHAIN: not 8-LYSINE 3/4 -VASOPRESSIN", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, vol. 68, no. 5, 1 May 1971 (1971-05-01), pages 1006 - 1009, XP001007913, ISSN: 0027-8424, DOI: 10.1073/PNAS.68.5.1006 * |
P. E. OYER; S. CHO; J. D. PETERSON; D. F. STEINER, J. BIOL. CHEM., vol. 246, 1971, pages 1375 - 1386 |
PU WANG ET AL: "Fmoc-Protein Synthesis: Preparation of Peptide Thioesters Using a Side-Chain Anchoring Strategy", INTERNATIONAL JOURNAL OF PEPTIDE RESEARCH AND THERAPEUTICS ; FORMERLY KNOWN AS LETTERS IN PEPTIDE SCIENCE, KLUWER ACADEMIC PUBLISHERS, DO, vol. 11, no. 2, 1 June 2005 (2005-06-01), pages 117 - 123, XP019287619, ISSN: 1573-3904 * |
T. W. GREENE: "Protecting Groups in Organic Synthesis", 1999, JOHN WILEY & SONS, INC. |
W. KEMMLER; J. D. PETERSON; D. F. STEINER, J. BIOL. CHEM., vol. 246, 1971, pages 6786 - 6791 |
ZUBAY: "Biochemistry", 1983, ADDISON-WESLEY PUB. CO. |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018108154A1 (en) | 2016-12-16 | 2018-06-21 | 中国医学科学院医药生物技术研究所 | Polymyxin derivative, preparation method and application thereof |
Also Published As
Publication number | Publication date |
---|---|
CN104428314A (en) | 2015-03-18 |
EP2838915B1 (en) | 2018-05-30 |
US20210388051A1 (en) | 2021-12-16 |
NZ631001A (en) | 2017-05-26 |
CA2870891A1 (en) | 2013-10-24 |
BR112014026077B1 (en) | 2022-03-08 |
US20160031962A1 (en) | 2016-02-04 |
AU2013250755A1 (en) | 2014-11-06 |
BR112014026077A2 (en) | 2017-06-27 |
HK1203525A1 (en) | 2015-10-30 |
IN2014DN09089A (en) | 2015-05-22 |
EP2838915A1 (en) | 2015-02-25 |
CA2870891C (en) | 2022-04-05 |
IL235183B (en) | 2018-01-31 |
CN104428314B (en) | 2021-11-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210388051A1 (en) | Solid phase peptide synthesis of insulin using side chain anchored lysine | |
EP3398960B1 (en) | Method for preparing semaglutide | |
US10183966B2 (en) | Solid phase peptide synthesis via side chain attachment | |
AU2007214088B2 (en) | Synthesis of glucagon-like peptide | |
US20080287650A1 (en) | High purity peptides | |
US20140350219A1 (en) | Method for solid phase synthesis of liraglutide | |
WO2013098802A2 (en) | Solid phase peptide synthesis via side chain attachment | |
CA2024855C (en) | Process and intermediates for producing glucagon | |
CN112912390B (en) | GLP-1 analogues and methods of preparation | |
US11566058B2 (en) | Process for the preparation of high purity glucagon | |
AU2008271608A1 (en) | Process for the production of pramlintide | |
EP3765488A1 (en) | Process for the manufacture of pthrp analogue | |
EP3986919A1 (en) | Process for the manufacture of glucagon | |
KISO et al. | Efficient solid phase peptide synthesis: Use of methanesulfonic acid α‐amino deprotecting procedure and new coupling reagent, 2‐(benzotriazol‐1‐yl) oxy‐1, 3‐dimethylimidazolidinium hexafluorophosphate (BOI) | |
KR102159138B1 (en) | Solid phase peptide synthesis via side chain attachment | |
AU2013250755B2 (en) | Solid phase peptide synthesis of insulin using side chain anchored lysine | |
CA2807162C (en) | Solid phase peptide synthesis via side chain attachment | |
CN114945580B (en) | Method for synthesizing south Ji Botai | |
US20240002460A1 (en) | A process for producing egf | |
CN111018963A (en) | Preparation method of glucagon |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13726299 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2870891 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2013250755 Country of ref document: AU Date of ref document: 20130419 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013726299 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14395313 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112014026077 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112014026077 Country of ref document: BR Kind code of ref document: A2 Effective date: 20141020 |